Person:
AKYÜZ, GÜLSEREN DERYA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

AKYÜZ

First Name

GÜLSEREN DERYA

Name

Filters

2007 - 200922010 - 20201
Reset filters

Settings

Has files: false × Subject: VERTEBRAL FRACTURES ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis
    (BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK, 2020) AKYÜZ, GÜLSEREN DERYA; Ozsoy-Unubol, Tugba; Akyuz, Gulseren; Mirzayeva, Samaya; Guler, Tuba
    Objectives: This study aims to evaluate pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis (OP). Patients and methods: Between May 2016 and January 2018, a total of 138 patients (mean age 63.78 years; range, 50 to 70 years) with postmenopausal OP were retrospectively analyzed. All patients were previously treated with denosumab (DEN) and parenteral forms of bisphosphonates such as zoledronic acid (ZOL) and ibandronate (IBN). The pain severity was evaluated using the Visual Analog Scale (VAS) and Brief Pain Inventory-Short Form (BPI-SF). The quality of life was evaluated using the Quality of Life Questionnaire of the European Foundation for Osteoporosis (Qualeffo-41). For the evaluation of patient satisfaction, a three-item questionnaire including satisfaction with the medication, route, and frequency of administration was applied. Results: Of the patients, 50 received DEN, 48 received ZOL, and 40 received IBN treatment. There was no significant difference in any of the pain parameters. All domains of the Qualeffo-41 were similar among the three groups. The patients in the DEN group were more satisfied with their medication (DEN: 88%, ZOL: 43.75%, and IBN: 52.5%), its administration route (DEN: 84%, ZOL: 43.8%, and IBN: 57.5%), and the frequency of its administration (DEN: 84%, ZOL: 56.25%, and IBN: 52.5%) (p=0.0001). Conclusion: Neither of the medication showed a superior effect on quality of life. However, patients were more satisfied with medications used in a six-month interval and applied subcutaneously. Of these three treatment options, DEN seems to be a step ahead in terms of patient satisfaction.
  • No Thumbnail Available
    PublicationMetadata only
    The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain
    (SPRINGER LONDON LTD, 2007) AKYÜZ, GÜLSEREN DERYA; Ofluoglu, D.; Akyuz, G.; Unay, O.; Kayhan, O.
    The purpose of this study was to evaluate the efficacy of calcitonin on beta-endorphin levels in female patients experiencing back pain associated with postmenopausal osteoporosis. The secondary purpose was to assess the pain and quality of life in these patients. There were 30 patients with a mean age of 58.2 +/- 5.4 years in the treatment group and 26 patients with a mean age of 58.8 +/- 5.2 years in the placebo group in this randomized, placebo-controlled study. The patients subcutaneously received 100 IU salmon calcitonin or placebo injections and 1,000 mg elementary calcium for 2 weeks. Baseline plasma beta-endorphin levels were measured and repeated after 2 weeks. Patients' pain and quality of life (QOL) were evaluated by using the Visual Analogue Scale, Modified Face Scale, Beck Depression Index, and Nottingham Health Profile. Patients' global assessment of disease activity was also performed at baseline and at the end of the first and second week. We found that plasma beta-endorphin levels in the treatment group were significantly higher than the placebo group at the end of the second week (p < 0.001). Although pain and QOL scores were improved at the end of the second week in both groups (p < 0.05), the improvement in the treatment group was more significant when compared with the placebo group (p < 0.05). Therefore, calcitonin is an analgesic agent, as it increases the plasma beta-endorphin levels in patients with postmenopausal osteoporosis, which consequently improves QOL.
  • No Thumbnail Available
    PublicationMetadata only
    Relationship between arm span and height in postmenopausal osteoporotic women
    (SPRINGER HEIDELBERG, 2008) AKYÜZ, GÜLSEREN DERYA; Ofluoglu, Demet; Unlu, Feyza; Akyuz, Gulseren
    Osteoporosis is a progressive systemic skeletal disease characterized by low bone density and microarchitectural deterioration of the bone. A minimum 3-cm difference between arm span and height makes up one of the criteria for suspecting osteoporosis. Therefore, it is easy to determine osteoporotic women by measuring the proportion of height to the arm span. The purposes of this study are to assess the relationship between arm span and height and to compare them in postmenopausal and young healthy women. This was a randomized-controlled, prospective study. There were two groups in this study. Group I included 70 postmenopausal osteoporotic women and group II had 70 healthy young women. Height, weight and arm span of the individuals were measured in all subjects. Bone mineral density and radiological examination of spine were also evaluated. Mean age of postmenopausal women was 64.4 +/- 8.6 years and it was 27.3 +/- 3.5 years in young healthy women. Mean height was 152 +/- 5.1 and 161.5 +/- 5.9 cm in group I and II, respectively. Mean arm span length was 159.6 +/- 6.3 cm in postmenopausal women and 163.5 +/- 6 cm in young healthy women. Mean arm span-height difference was significantly higher in postmenopausal women when compared to healthy young women (7.7 +/- 3.6 and 2 +/- 2.9 cm, respectively, P < 0.001). We suggest that arm span measurements can be used in the estimation of youth height and age-related loss in stature in postmenopausal women.